NCT03383055 is a Phase 1 clinical trial of CMV-MVA Triplex Vaccine in Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.

Who is sponsoring NCT03383055?

NCT03383055 is sponsored by Masonic Cancer Center, University of Minnesota.

What drugs are being tested in NCT03383055?

Interventions in NCT03383055: CMV-MVA Triplex Vaccine.

What condition does NCT03383055 study?

NCT03383055 studies Lymphoma, Multiple Myeloma.

Is NCT03383055 still recruiting?

NCT03383055 is currently completed. Last updated 17 August 2021.

Last reviewed 2021-08-17 · How we verify

NCT03383055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Completed Phase 1 Last updated 17 August 2021

What this trial tests

Phase 1 trial testing CMV-MVA Triplex Vaccine in Lymphoma in 28 participants. Completed in 10 July 2021.

Timeline

16 November 2018

Primary endpoint
10 July 2021

10 July 2021

Quick facts

Lead sponsor	Masonic Cancer Center, University of Minnesota
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	16 November 2018
Primary completion	10 July 2021
Estimated completion	10 July 2021
Sites	1 location across United States

Drugs / interventions tested

CMV-MVA Triplex Vaccine — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →
Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Masonic Cancer Center, University of Minnesota

Who can join

18 and older, any sex, with Lymphoma or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at various days will be compared.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the NK cell platform for cancer immunotherapy.
Myers JA, Miller JS. · · 2021 · cited 977× · PMID 32934330 · DOI 10.1038/s41571-020-0426-7
Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.
Zuo W, Zhao X. · · 2021 · cited 51× · PMID 33887436 · DOI 10.1016/j.clim.2021.108727
Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.
Hu X, Wang HY, Otero CE, Jenks JA, et al · · 2022 · cited 23× · PMID 35704747 · DOI 10.1146/annurev-virology-100220-010653
CMV Prevention and Treatment in Transplantation: What's New in 2019.
Stern A, Papanicolaou GA. · · 2019 · cited 23× · PMID 31732823 · DOI 10.1007/s11908-019-0699-0
The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.
Gomes AC, Griffiths PD, Reeves MB. · · 2019 · cited 11× · PMID 31319553 · DOI 10.3390/vaccines7030067
Process engineering of natural killer cell-based immunotherapy.
Motallebnejad P, Kantardjieff A, Cichocki F, Azarin SM, et al · · 2023 · cited 10× · PMID 37142447 · DOI 10.1016/j.tibtech.2023.03.018
CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation.
Rashidi A, La Rosa C, Curtsinger J, Cao Q, et al · · 2022 · cited 6× · PMID 35272066 · DOI 10.1016/j.jtct.2022.03.003

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Masonic Cancer Center, University of Minnesota trials

Trials by the same sponsor.

NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03383055 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 17 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03383055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing